Zealand Pharma (CSE: ZELA) shares climbed 3.8% to DKK 943.50, buoyed by CEO remarks on potential partnerships for its weight loss drug. Jefferies predicts significant sales potential for the amylin pipeline, maintaining a "buy" rating amidst favorable trial results.